Clinical trials: Nonvalvular Atrial Fibrillation
Atrial Fibrillation, Atrial Flutter
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk…
- Trial name
- ARISTOTLE (NCT00412984)
- Testing
- warfarin, apixaban
- Where
- 1,111 sites in United States, Argentina and 39 more
- Volunteers
- 20,976 people
- Sponsor
- Bristol-Myers Squibb
Nonvalvular Atrial Fibrillation
The Adherence to Oral Anticoagulant in Chinese Patients With NVAF
Investigate the compliance of oral anticoagulants in Chinese NVAF patients and find out the causes, so as to provide basis for formulating effective measures to improve the compliance of oral anticoagulants.
- Trial name
- NVAF (NCT04942873)
- Testing
- adherence
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Atrial Fibrillation
Japanese Pradaxa PMS, Long Term
The study objective is to confirm appropriate use and safety profile of Prazaxa® Capsules in real-world setting after the availability of idarucizumab
- Trial name
- NCT03175198
- Testing
- Prazaxa® Capsules
- Where
- Japan
- Volunteers
- 5,660 people
- Sponsor
- Boehringer Ingelheim
Stroke, Acute, Atrial Fibrillation
SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)
The purpose of this study is to determine choice of anticoagulant therapy during acute and chronic stages of ischemic stroke/TIA and short- and long-term outcomes, including stroke recurrence and bleeding complications, in…
- Trial name
- SAMURAI-NVAF (NCT01581502)
- Testing
- This is an observational study.
- Where
- 16 sites in Japan
- Volunteers
- 1,000 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Nonvalvular Atrial Fibrillation, Aspirin
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
The goal of this clinical trial is to verify that Non-Antithrombotic Therapy (NAPT) followed by Oral Anticoagulants (OAC) monotherapy for 45 days after Left Atrial Appendage Closure (LAAC) is non-inferior to Single Antiplatelet…
- Conditions
- Nonvalvular Atrial Fibrillation, Aspirin, Non-Antithrombotic Therapy, High Bleeding Risk
- Trial name
- NCT07125417
- Testing
- Single Antiplatelet Therapy or No Therapy (Control), Non-Antithrombotic Therapy
- Where
- 21 sites in Japan
- Volunteers
- 500 people
- Sponsor
- OCEAN-SHD Study Group
Atrial Fibrillation
Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation
To investigate the safety and efficacy of long-term use of Prazaxa® Capsules in patients with nonvalvular atrial fibrillation for preventing the occurrence of ischemic stroke or systemic embolism (SEE).
- Trial name
- NCT01491178
- Testing
- Prazaxa
- Where
- 1,164 sites in Japan
- Volunteers
- 6,772 people
- Sponsor
- Boehringer Ingelheim